Physician profile
Nicholas Eugene Manuel
NPI 1275037939
$2,615.39
in general payments reported to CMS, 2019-2025
11 companies · $83.85 in 2025
The $83.85 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $363 · 2023: $933 · 2024: $1,235 · 2025: $83.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $571.48 | 2023-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $411.76 | 2022-2023 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $390.32 | 2023-2024 | Sogroya |
| Corcept Therapeutics | $352.29 | 2023-2024 | Korlym |
| Amgen INC. | $233.53 | 2022-2024 | Evenity |
| Averitas Pharma INC. | $168.37 | 2023-2024 | Qutenza |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Alexion Pharmaceuticals, INC. | $124.73 | 2024 | |
| Esperion Therapeutics, INC. | $123.35 | 2022 | |
| Astellas Pharma US INC | $96.95 | 2024 | Veozah |
| Beta Bionics, INC. | $17.62 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Manuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.